BHCM
LAB icon

Brevan Howard Capital Management’s Standard BioTools LAB Stock Holding History

Brevan Howard Capital Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$199K Buy
+242,320
New +$229K ﹤0.01% 1907
2024
Q2 		– Sell
-116,905
Closed -$317K – 1239
2024
Q1 		$317K Buy
+116,905
New +$282K ﹤0.01% 635

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Brevan Howard Capital Management's LAB Position: Q2 2026 in Review

Brevan Howard Capital Management opened a new position in Standard BioTools (LAB) in Q2 2026: 242,320 shares worth $199K. The stake represents ﹤0.01% of the portfolio and ranks #1907 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in LAB as recently as Q1 2024.

Brevan Howard Capital Management first reported a position in LAB in Q1 2024 and has held it in 2 quarters since. The position peaked at $317K in Q1 2024. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • Brevan Howard Capital Management held 242,320 shares of Standard BioTools worth $199K as of Q2 2026.
  • Standard BioTools was a new Brevan Howard Capital Management position in Q2 2026.
  • Standard BioTools made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1907 holding.
  • Brevan Howard Capital Management first reported a position in Standard BioTools in Q1 2024 and has held it in 2 quarters since.
  • Brevan Howard Capital Management's Standard BioTools position peaked at $317K in Q1 2024.
  • 143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.